CSCO guidelines for colorectal cancer version 2023: Updates and insights
Colorectal cancer (CRC) is the second most common cancer and the most common type of gastrointestinal cancer with rapidly increasing incidence and mortality in China. Since the first edition of the Chinese Society of Clinical Oncology (CSCO) guideline was published in 2017, the guideline has been updated annually according to the latest results of clinical research at home and abroad, the accessibility of drugs and the opinions of CSCO experts. Here, we present the main updates of the 2023 version compared to the 2022 version.
Stomach cancer burden in China: Epidemiology and prevention
In 2020, stomach cancer was the fifth most commonly diagnosed cancer and the fourth leading cause of cancer-related death worldwide. Due to the relatively huge population base and the poor survival rate, stomach cancer is still a threat in China, and accounts for nearly half of the cases worldwide. Fortunately, in China, the incidence and mortality rates of stomach cancer presented a declining trend owing to the change of individual life styles and the persistent efforts to prevent stomach cancer from the governments at all levels. Helicobacter pylori (H. pylori) infection, poor eating habits, smoking, history of gastrointestinal disorders, and family history of stomach cancer are the main risk factors for stomach cancer in China. As a result, by taking risk factors for stomach cancer into account, specific preventive measures, such as eradicating H. pylori and implementing stomach cancer screening projects, should be taken to better prevent and decrease the burden of stomach cancer.
Burden of liver cancer: From epidemiology to prevention
In this review, we offer a concise overview of liver cancer epidemiology in China and worldwide from the official databases of GLOBOCAN 2020 and the National Cancer Registry in China. We also summarized the evidence for the main risk factors associated with liver cancer risk and discuss strategies implemented in China to control the liver cancer burden. Overall, liver cancer was the sixth most commonly diagnosed cancer and the third leading cause of cancer-related death worldwide in 2020. Although China contributed to nearly half of cases across the world alone, the incidence and mortality rates of liver cancer presented a declining trend owing to the persistent efforts from the governments at all levels. The current liver cancer burden in China still faces an arduous challenge due to the relatively large population base as well as the substantially low survival rate (12.1%). To better control the liver cancer burden with the lowest cost, specific measures should be conducted by reducing exposure to established risk factors such as hepatitis B infection and aflatoxin.
Shin-Hoo Park, Ye-Rim Shin, Hoon Hur, Chang Min Lee, Jae Seok Min, Seung Wan Ryu, Hyun Dong Chae, Oh Jeong, Chang-In Choi, Kyo-Young Song, Ho Goon Kim, Ye Seob Jee, Kwang Hee Kim, Jeong Goo Kim, Kyung Sook Yang, Hua Huang, Sungsoo Park
Wei Liu, Ziyang Wu, Tong Sun, Shuyao Liang, Jun Zhu, Suodi Zhai, Division of Therapeutic Drug Monitoring of Chinese Pharmacological Society, Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association, Oncology Society of Chinese Medical Association, Nursing Branch of China International Exchange and Promotive Association for Medical and Healthcare, Division of Drug-induced Diseases of Chinese Pharmacology Society